At least a 6 month interval since completion of prior radiation
Low grade NHL: with < 6 month duration of CR between courses of conventional therapy
Variceal bleeding within 1 month prior to study registration
Predisposing characteristics for acute pancreatitis in the last month prior to randomization.
Patient with irregular cycles (more than once a month)
Participant who is breastfeeding or planning to breastfeed for a month post last dose of study agent
Inability to start the protocol treatment within 1 month after study enrollment
Administration of chemotherapy within the last 1 month
History of active immunotherapy in the previous month.
No prior radiation therapy or chemotherapy within 1 month of study enrollment
Active or recent (prior 6 month) invasive fungal infection without interdisciplinary (ID) consult and approval
Subject had surgery (excluding line insertions) within 1 month of the first dose of study drug or has lingering wound complications.
Rx with an investigational drug w/in 1 month of infusion, other than for treatment of their underlying disease
Clinically relevant infection of any kind within the month preceding enrollment (example, active hepatitis C, pneumonia)
Brain MRI within one month prior to enrollment
Low grade NHL–with < 6 month duration of CR between courses of conventional therapy
Patients who have had influenza, hepatitis, or other vaccines within a month prior to initiation of study drugs
Corticosteroids will be allowed at enrollment and during the first month of treatment with T-DM1 after SRS, up to a dose of no more than 10 mg of dexamethasone daily or equivalent; patients that need to continue corticosteroids after the initial month will be allowed to continue in the protocol treatment if no further increase in dose is necessary; patients that need increase in dose of corticosteroid after initial month will be taken off protocol treatment
Chemotherapy (current, within the last month, or anticipated in the next 7 months)
Radiation therapy in the month prior to enroll
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol
The subject has a prior history of unrelated neoplastic disease, and has received systemic therapy for the secondary malignancy within the twelve (12) month period preceding the screening evaluation
Disease staging approximately within one month of treatment
Radiation therapy in the month prior to enrollment
Illicit drug use within the last month
Is in an immunosuppressed state (e.g. HIV +, use of chronic steroids [> 1 month])
Progressive lymphocytes with an increase of >= 50% over a 2-month period or an anticipated doubling time of less than 6 months OR
PART 2: Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
Patients with myelodysplastic syndromes refractory (primary or acquired resistance) to hypomethylating agents; at least 4 1-month cycles of prior decitabine or SGI-110 (guadecitabine) OR 6 1-month cycles of 5-azacytidine (intravenous [IV], subcutaneous, or oral) is required unless the patient has progressive disease prior to completing the required number of cycles
Patients who have had flu, hepatitis, or other vaccines within a month prior to initiation of study drugs
Concurrent uncontrolled medical illness that is deemed by the investigator to have potential to interfere with the delivery of chemotherapy for a six month time period
Patients who have previously taken omega-3 fatty acid within 1 month prior to study enrollment
Patients who have an uncontrolled infection (presumed or documented) with progression after appropriate therapy for greater than one month
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol; however, cell harvesting by leukapheresis may be performed before one month from prior therapy if the study investigators consider that it will not have a detrimental impact on the generation of the two cell therapies in this protocol
Use of oral glucocorticoids within 1 month of screening
Active pneumonia within 1 month prior to starting treatment
Active or recent (prior 6 month) invasive fungal infection without infectious diseases (ID) consult and approval
Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
Received immunosuppression post hematopoietic transplant within 1 month of study entry
Clinically relevant infection of any kind within the month preceding enrollment (eg, active hepatitis C, pneumonia)
Clinically relevant infection of any kind within the preceding month of enrollment
recent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery
Radiation therapy in the month prior to enroll
Active or recent (prior 6 month) invasive fungal infection unless cleared by innovation and development (ID) consult
Anticipated lifespan greater than 3 month
Signed informed consent for the focal laser ablation (FLA) treatment through the 12 month follow up visit
Anti-angiogenic therapy within the last month
Age < 18 years and > 1 month (< 1 month upon approval by Sponsor)
night sweats for > 1 month without evidence of infection
Patients of fertile age who refuse contraception for a twelve month period post-transplant
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol; however, cell harvesting by leukapheresis may be performed before one month from prior therapy if the study investigators consider that it will not have a detrimental impact on the generate of the two cell therapies in this protocol
Disease staging approximately within one month of treatment
The subject must be willing to apply the medications twice daily for 1 month
History of myocardial infraction (MI) within 6 month prior to starting study treatment
Anticipated lifespan greater than 6 month.
Patients may not be receiving or have received any other investigational agents during/or within 1 month prior to treatment with oregovomab or nelfinavir
Having smoked at least one cigarette within 1 month of cancer diagnosis
Patient taking varenicline or bupropion within one month of study enrollment
Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 1 month after the last dose of sorafenib
Prior daily use of tadalafil or other long-acting phosphodiesterase-5 (PDE5) inhibitors for one month or greater
Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
Cancer vaccines and convection-enhanced therapies: interval >= 1 month before study enrollment
Subjects who received any investigational medication, prior local therapy for pancreas cancer , or any significant change in treatment within 1 month prior to screening
Use of systemic glucocorticoids such as prednisone or Decadron in the last month
Participants may have received prior TKI therapy, however must be on a stable dose of their current TKI for at least one month prior to enrollment
If spinal metastases is within previously irradiated field, there must be a 6 month interval between prior radiation course and study registration
Low-grade NHL with < 6 month duration of CR between courses of conventional therapy
Received any of the following within the specified time frame prior to the Month 1-Day 1 Visit:
Chemotherapy or investigational antineoplastic drug within 1 month of planned initiation of vaccine therapy
Receipt of treatment known to potentially affect the course of AA within last month
Received thrombolytic agents w/in the previous month
No seizures, focal weakness of any extremity (by neurologic exam), or stroke symptoms in the past month
Current (within last month) use of chemotherapy for breast or other malignancy
Recent (within last month) or current intensive manual lymphatic drainage (MLD) and/or short stretch bandage use
If patients have received radiation therapy, there must be a one-month washout period
Patients having received radiation therapy in the month prior to enrollment
More than one previous episode of CDAD in the 3-month period prior to randomization.
Chest X-ray within 1 month of registration
Patients in this study may not use vaccines for the treatment of cancer or prevention of disease unless indicated as a component of the protocol regimen (including those for common medical conditions) for up to one month pre and post dosing with ipilimumab
Traumatic catheterization within 1 month
Glaucoma diagnosed within one month prior to study Day 1.
Treatment with highly active antiretroviral therapy (HAART) for at least 1 month
Patients that start chemotherapy or radiotherapy during the study time (1 month post diagnostic bronchoscopy), will be excluded from the study
Radiation therapy in the month prior to enroll
No recent history (=< 90 days) of substance abuse (outside of tobacco) defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) as:\r\n* If male, drinking > 14 alcoholic beverages per week for past 1 month\r\n* If female, drinking > 7 alcoholic beverages per week for past 1 month\r\n* Use of cocaine, heroin, club drugs (i.e., 3,4-methylenedioxymethamphetamine (MDMA)/“ecstasy”), methamphetamine, or hallucinogens (e.g., lysergic acid diethylamide [LSD]) at any time during the past 1 month\r\n* Use of marijuana on a weekly basis for the past 1 month
Within one month (+/- 1 month) of starting chemotherapy or within two weeks (+/- 2 weeks) of starting radiation therapy (may be prior to or after starting treatment)
PATIENT EXCLUSION: Life expectancy of < 1 month
Have outpatient visits at least once a month
Use of an investigational drug within 1 month prior to dosing
Major surgery/surgical therapy for any cause within 1 month prior to pasireotide administration; patients should have recovered and have a good clinical condition before entering the study
Not currently regularly practicing yoga (defined as at least once a month)
Chronic treatment with any inhaled steroid for > 1 month in past three months
Treatment with montelukast or zafirukast for > 1 month in past three months
Treatment with systemic steroids for > 1 month in past three months
Patients who will be receiving surgery or adjuvant chemotherapy within 1 month following radiation treatment
Female breast cancer survivor who is over 1 month and less than 24 months beyond the completion of primary therapy (surgery, radiation, and chemotherapy).
Participants must be willing and able to travel to CUMC for data collection and optional blood draws at two baseline visits, 6-month and 12-month visit; if needed and depending on staff availability, optional blood draws can be completed at a participant’s home by a certified phlebotomist from our research team
Acute coronary event within the past month
Chronic glucocorticoid or acute glucocorticoid or other synthetic steroid intake within the last month
Surgery or hospitalization within the last month
Surgical treatment in the previous month
ALS PATIENTS: Already on a stable dose of riluzole for at least one month
Severe anemia (hemoglobin [Hb] < 7g/L) if documented in the last month and not corrected prior to study enrollment
Patients must be willing to adhere to the PNP intervention and the entire 6-month study
Patients who have lost >= 5% of their usual body weight over the preceding 1 month
Received filgrastim (GCSF) treatment within one month of enrollment
Oncologists who treat at least 2 advanced cancer patients per month at a study participating hospital
History of using any of the following medications, regardless of dose, for at least 1 month, within 3 months of enrollment: anabolic agents, glucocorticoids (does not include inhaled glucocorticoids), growth hormone, parathyroid hormone (PTH)
Severe anemia (hemoglobin [Hb] < 7 g/L) if documented in the last month and not corrected prior to study enrollment; extra blood work will not be drawn unless the patient already has the lab abnormalities documented and need to be corrected
Life expectancy < 1 month or current hospice care
No planned surgery anticipated in the 3-month intervention period
At least 1 month from any major surgery to start of intervention, including colostomy reversal (Port-A-Cath removal excluded)
Narcotics, antidepressants or other medications for the treatment of CIPN are permitted, if patient on a stable dose for at least one month prior to enrollment
Recent steroid treatment within the last month
Presence of hot flashes for >=1 month prior to study entry
Patient is willing to delay prostate biopsy for a 3-month finasteride treatment
Patient is willing to take finasteride 5 mg orally daily for 3-month treatment period
Patient must be above the age of 1 month as of the start date of study treatment.
Reports conducting at least 20 new initial screenings per month
Smokers who are receiving other tobacco treatment services or have used cessation medications (NRT, bupropion, varenicline) within the past month
Prior use of topical or systemic therapies that might interfere with the evaluation of the study medication during the study, within a 3 month washout period from the time of the screening visit
A cardiovascular event in the past month
Have been non-daily smokers for at least the previous year (< or = 27 days/month);
Low grade NHL – with < 6 month duration of CR between courses of conventional therapy
Provided a secondary phone or email contact to ensure one month follow-up survey completion
Suffering from a terminal illness with less than 12 month life expectancy
Terminal illness with less than 12 month life expectancy
Willing to undergo a history and physical at baseline and 12 months and be contacted periodically by the trial coordinator during the 12 month study period
STUDY I: >= 1 month of e-cigarette use
History of DHA supplementation > 200 mg/day in the month preceding study entry
A patient who has not received systemic or loco-regional treatment of the tumor within the last month.
Intravenous (IV) contrast exposure in the past 1 month
Less than 1 month since any prior prostate biopsy (to decrease false positive from inflammation)
HEALTHY VOLUNTEER: Exposure to ultrasound contrast agents (UCAs) in the 1 month prior to study initiation
The patient must agree at the time of study entry to undergo clinically indicated biopsy(ies) or 24-month period of follow-up, as needed, to resolve the etiology of their IPN(s) or lung mass(es)
Women who will receive or have already received a breast MRI within one month of the CESM
Have undergone chemotherapy or radiation therapy within the previous one month
Patients with a blood creatinine level > 2.0 mg/dl within a month of this procedure
Diabetic patients with a blood creatinine level > 1.5 mg/dl within a month of this procedure
Participants unwilling to complete the protocol (24 month duration)
Use of antibiotics one (1) month prior to or during this study
Have undergone chemotherapy or radiation therapy within the previous one month
Less than 1 month since any prior prostate biopsy (to decrease false positive uptake from inflammation)
Core biopsies obtained within 1-month of MRI/MRE
Willing to use contraception during and for 1 month after completion of the study
The subject has received, or is scheduled to receive, another IMP from 1 month before to 1 month after inclusion in this study
A history of antibiotic use within one month prior to initial PSA level measurement
Current or prior systemic use of corticosteroids in the past month
Recipient of vaccines within 1 month of or during study drug treatment.
Receiving treatment for advanced lung cancer for over one month before enrollment; OR
TIPs INCLUSION: Planning on remaining in NYC for at least 1 year, (with no vacations or trips to exceed one month)
past six month use of any e-cigarette
